CN106659742B - 表达免疫应答刺激细胞因子以吸引和/或激活免疫细胞的基因修饰间充质干细胞 - Google Patents

表达免疫应答刺激细胞因子以吸引和/或激活免疫细胞的基因修饰间充质干细胞 Download PDF

Info

Publication number
CN106659742B
CN106659742B CN201580045089.6A CN201580045089A CN106659742B CN 106659742 B CN106659742 B CN 106659742B CN 201580045089 A CN201580045089 A CN 201580045089A CN 106659742 B CN106659742 B CN 106659742B
Authority
CN
China
Prior art keywords
cells
promoter
cell
tumor
immune
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201580045089.6A
Other languages
English (en)
Chinese (zh)
Other versions
CN106659742A (zh
Inventor
克里斯蒂安·根特尔
斯特凡诺斯·泰奥哈里斯
费利克斯·赫尔曼
拉尔夫·哈斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Apceth GmbH and Co KG
Original Assignee
Apceth GmbH and Co KG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Apceth GmbH and Co KG filed Critical Apceth GmbH and Co KG
Publication of CN106659742A publication Critical patent/CN106659742A/zh
Application granted granted Critical
Publication of CN106659742B publication Critical patent/CN106659742B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/428—Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Wood Science & Technology (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN201580045089.6A 2014-08-18 2015-08-18 表达免疫应答刺激细胞因子以吸引和/或激活免疫细胞的基因修饰间充质干细胞 Active CN106659742B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14181283.4 2014-08-18
EP14181283 2014-08-18
PCT/EP2015/068942 WO2016026854A2 (en) 2014-08-18 2015-08-18 Genetically modified mesenchymal stem cells expressing an immune response-stimulating cytokine to attract and/or activate immune cells

Publications (2)

Publication Number Publication Date
CN106659742A CN106659742A (zh) 2017-05-10
CN106659742B true CN106659742B (zh) 2021-09-03

Family

ID=51352460

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201580045089.6A Active CN106659742B (zh) 2014-08-18 2015-08-18 表达免疫应答刺激细胞因子以吸引和/或激活免疫细胞的基因修饰间充质干细胞

Country Status (8)

Country Link
US (2) US20170239297A1 (https=)
EP (2) EP3656387A3 (https=)
JP (1) JP6712993B2 (https=)
CN (1) CN106659742B (https=)
AU (1) AU2015306231B2 (https=)
CA (1) CA2956987C (https=)
IL (1) IL250388B (https=)
WO (1) WO2016026854A2 (https=)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201202319D0 (en) 2012-02-10 2012-03-28 Orbsen Therapeutics Ltd Stromal stem cells
PT3107573T (pt) * 2014-02-19 2019-01-10 Merck Patent Gmbh Imunoterapia com il-12 visada ao cancro
PL3411473T3 (pl) * 2016-04-01 2021-05-04 JunctuCell Biomed Manufacturing GmbH Mezenchymalne komórki macierzyste nasilające aktywność antynowotworową immunoterapii
WO2018071295A1 (en) * 2016-10-10 2018-04-19 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for inducible production of anti-inflammatory cytokines
CN108148862B (zh) 2016-12-05 2019-03-08 上海优卡迪生物医药科技有限公司 一种封闭pdl1的用于抑制免疫逃脱的car-t转基因载体及其构建方法和应用
WO2018170390A1 (en) * 2017-03-17 2018-09-20 Senti Biosciences, Inc. Immunomodulating cell circuits
CA3059249A1 (en) * 2017-04-07 2018-10-11 Cynata Therapeutics Limited Method for treating a side effect of chimeric antigen receptor (car) t cell therapy
EP4317422A3 (en) * 2017-04-13 2024-05-01 Senti Biosciences, Inc. Combinatorial cancer immunotherapy
CN107184603B (zh) * 2017-06-01 2020-06-30 刘未斌 一种治疗肿瘤的药物组合
CN107184602B (zh) * 2017-06-01 2020-06-30 刘未斌 一种治疗肿瘤的药物组合
US20200323922A1 (en) * 2017-06-16 2020-10-15 Cynata Therapeutics Limited Method for treating a side effect of immunotherapy
WO2019067491A1 (en) * 2017-09-29 2019-04-04 Oncocyclist, Inc. COMPOSITION AND METHOD FOR TREATING CELL PROLIFERATION
US12016882B2 (en) 2017-11-22 2024-06-25 The Brigham And Women's Hospital, Inc. Method of treating glioblastoma multiforme
TR201900059A2 (tr) 2018-01-05 2019-07-22 Gnt Biotech & Medicals Corp Bi̇r farmasöti̇k kombi̇nasyon ve tümör mi̇kroortaminin ve i̇mmünoterapi̇ni̇n regülasyonu i̇çi̇n yöntem
AU2019206643A1 (en) * 2018-01-12 2020-07-23 Rutgers, The State University Of New Jersey Cell reprogramming therapy
WO2019144945A1 (en) * 2018-01-25 2019-08-01 I-Mab Anti-pd-l1 antibody and il-7 fusions
JP2021512950A (ja) 2018-02-02 2021-05-20 エスエル・ベクシジェン・インコーポレイテッドＳｌ Ｖａｘｉｇｅｎ， Ｉｎｃ． 新規なワクチンの免疫補助剤
US11458171B2 (en) * 2018-03-21 2022-10-04 China Medical University Engineering stem cells for cancer therapy
CN108864288A (zh) * 2018-04-26 2018-11-23 上海怡豪生物科技有限公司 乳腺癌的双靶点car-t治疗载体及其构建方法和应用
CN110527696A (zh) * 2018-06-13 2019-12-03 中山大学 一种IFNβ和FerritinH基因联合修饰的骨髓间充质干细胞及其制备方法和应用
CN108815188A (zh) * 2018-07-06 2018-11-16 浙江生创精准医疗科技有限公司 包含间充质干细胞制剂与免疫检查点抑制剂的肿瘤治疗组合物、试剂盒及其用途
US20210346430A9 (en) * 2018-08-26 2021-11-11 Oaiscell Biotechnologies Method for treating glioblastoma
US20220096544A1 (en) * 2018-09-20 2022-03-31 Cafa Therapeutics Limited Chemokine expressing cell and use thereof
WO2020077356A1 (en) * 2018-10-12 2020-04-16 Icell Gene Therapeutics Llc CHIMERIC ANTIGEN RECEPTORS (CARs) COMPOSITIONS AND METHODS OF USE THEREOF
US11419898B2 (en) 2018-10-17 2022-08-23 Senti Biosciences, Inc. Combinatorial cancer immunotherapy
SG11202103317XA (en) 2018-10-17 2021-05-28 Senti Biosciences Inc Combinatorial cancer immunotherapy
CN109593725A (zh) * 2018-12-25 2019-04-09 河北生命原点生物科技有限公司 一种重组间充质干细胞及其应用
CN113795755A (zh) * 2019-02-14 2021-12-14 全国儿童医院研究所 质膜颗粒、脂质体和外泌体用于测定免疫细胞效力的用途
CN109762820B (zh) * 2019-02-18 2020-07-28 河北佑仁生物科技有限公司 一种骨髓间充质干细胞特异性启动元件在干细胞中的应用
CA3135618A1 (en) * 2019-04-02 2020-10-08 The General Hospital Corporation Methods to enhance t cell regeneration
CN111849905B (zh) * 2019-04-18 2023-03-24 上海交通大学 间充质干细胞靶向运输趋化因子和细胞因子的免疫疗法
CN111139222B (zh) * 2019-05-30 2020-12-29 北京双因生物科技有限公司 一种重组间充质干细胞及其制备方法和用途
WO2021038289A1 (en) * 2019-08-23 2021-03-04 Orbsen Therapeutics Limited Compositions for monocyte and macrophage polarization and methods of use
US20230105923A1 (en) * 2020-03-26 2023-04-06 Agency For Science, Technology And Research A method and system for introducing one or more exogenous substances into an immune cell
WO2021239308A1 (en) * 2020-05-27 2021-12-02 Universität Zürich Viral vectors expressing therapeutic proteins specifically in myeloid cells and microglia
JP7758370B2 (ja) * 2020-07-16 2025-10-22 チャンジェン セラピューティクス （シャンハイ） カンパニー リミテッド 間葉系幹細胞によるケモカインおよびサイトカイン送達を標的とする免疫療法
US20230399622A1 (en) * 2020-10-16 2023-12-14 Fundació Centre De Regulació Genòmica Therapy for degenerative disease and tissue damage
CN114507643A (zh) * 2020-10-29 2022-05-17 未来智人再生医学研究院(广州)有限公司 一种表达il-2的多能干细胞衍生物及应用
CN114426953A (zh) * 2020-10-29 2022-05-03 未来智人再生医学研究院(广州)有限公司 一种表达il-12的多能干细胞衍生物及应用
CN114717232A (zh) * 2020-12-22 2022-07-08 未来智人再生医学研究院(广州)有限公司 表达irf-1靶向抑制因子的多能干细胞及其衍生物与应用
WO2023274355A1 (zh) * 2021-07-02 2023-01-05 上海交通大学 改造的间充质干细胞和免疫效应细胞联合治疗肿瘤
IL312434A (en) * 2021-11-01 2024-06-01 Mam Holdings Of West Florida L L C Mesenchymal stem cells for the prevention and targeted treatment of cancer and other diseases
CN114480413B (zh) * 2022-01-14 2022-11-04 北京贝来生物科技有限公司 一种活化肿瘤免疫应答的基因修饰干细胞制备方法
CN115463155B (zh) * 2022-11-01 2023-05-23 卡瑞济(北京)生命科技有限公司 间充质干细胞的用途
CN117503952B (zh) * 2022-11-24 2025-09-16 中国药科大学 一种基于血小板的免疫激活系统及其制备方法和应用
WO2024137869A2 (en) * 2022-12-20 2024-06-27 City Of Hope Stem cells for delivery of oncolytic viruses
US20250333700A1 (en) * 2024-02-28 2025-10-30 Gene Solutions Joint Stock Company Modified k562 feeder cell line expressing factors that enhance the activation and proliferation of natural killer cells and a method for its production
WO2026069312A1 (en) 2024-09-24 2026-04-02 Yeda Research And Development Co. Ltd. Immune cells expressing an inducible therapeutic agent and uses thereof

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1842339A (zh) * 2003-06-27 2006-10-04 株式会社雷诺再生医学研究所 含有间叶细胞作为有效成分、治疗脑神经疾病的体内给药治疗剂
CN101083910A (zh) * 2004-09-10 2007-12-05 同源治疗公司 用于预防和治疗移植中的免疫应答的肝脏基质细胞
CN101778934A (zh) * 2007-05-24 2010-07-14 埃普塞斯有限责任两合公司 Cd34干细胞相关方法和组合物
CN101974485A (zh) * 2010-11-12 2011-02-16 苏州大学 具有最佳迁移能力的间充质干细胞的制备方法及其应用
CN102471753A (zh) * 2009-12-08 2012-05-23 伊利诺伊大学理事会 干细胞免疫调节应用方法和设备
CN102695517A (zh) * 2009-04-13 2012-09-26 埃普塞斯有限责任两合公司 经改造的间充质干细胞和用其治疗肿瘤的方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003073998A2 (en) 2002-03-02 2003-09-12 Board Of Regents, The University Of Texas System Local production and/or delivery of anti-cancer agents by stromal cell precursors
JPWO2005007176A1 (ja) * 2003-06-27 2006-08-31 株式会社レノメディクス研究所 間葉系細胞を有効成分とする体内投与用脳神経疾患治療薬
US20050002904A1 (en) 2003-07-03 2005-01-06 Wary Kishore K. Uses of vascular endothelial growth factor and type I collagen inducible protein (VCIP)
EP1757703A3 (en) 2005-08-24 2007-12-05 Medizinische Hochschule Hannover Self-inactivating retroviral vector
EP2019134A1 (en) 2007-07-26 2009-01-28 Vision 7 GmbH Gene therapy of chronic granulomatous disease
US9101597B2 (en) 2013-03-14 2015-08-11 The Administration Of The Tulane Educational Fund Immunoprotective primary mesenchymal stem cells and methods
WO2015035235A1 (en) * 2013-09-06 2015-03-12 Consejo Nacional De Investigaciones Cientificas Y Tecnicas (Conicet) Compositions and methods for increasing mesenchymal stromal cell migration to tumors
US11028143B2 (en) * 2014-01-21 2021-06-08 Novartis Ag Enhanced antigen presenting ability of RNA CAR T cells by co-introduction of costimulatory molecules
WO2016146819A1 (en) * 2015-03-18 2016-09-22 Apceth Gmbh & Co. Kg Hypoxia-induced expression of therapeutic proteins in mesenchymal stem cells

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1842339A (zh) * 2003-06-27 2006-10-04 株式会社雷诺再生医学研究所 含有间叶细胞作为有效成分、治疗脑神经疾病的体内给药治疗剂
CN101083910A (zh) * 2004-09-10 2007-12-05 同源治疗公司 用于预防和治疗移植中的免疫应答的肝脏基质细胞
CN101778934A (zh) * 2007-05-24 2010-07-14 埃普塞斯有限责任两合公司 Cd34干细胞相关方法和组合物
CN103263439A (zh) * 2007-05-24 2013-08-28 埃普塞斯有限责任两合公司 Cd34干细胞相关方法和组合物
CN102695517A (zh) * 2009-04-13 2012-09-26 埃普塞斯有限责任两合公司 经改造的间充质干细胞和用其治疗肿瘤的方法
CN102471753A (zh) * 2009-12-08 2012-05-23 伊利诺伊大学理事会 干细胞免疫调节应用方法和设备
CN101974485A (zh) * 2010-11-12 2011-02-16 苏州大学 具有最佳迁移能力的间充质干细胞的制备方法及其应用

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
Cytokines transduced bone marrow stromal cell lines promote immunohematopoietic reconstitution in mice after allogeneic bone;Ailing Li等;《Immunology Letters》;20050515;第98卷(第2期);第216-224页 *
IL-12 、IL-7 、IL-2 体外协同诱导人PBMC增殖和PBMC杀瘤活性的实验研究;徐红薇等;《中国免疫学杂志》;19980920;第14卷(第5期);第338页摘要，第339页左栏第2.1-2.2节，第340页左栏第3节 *
IL-7 Enhances the Responsiveness of Human T Cells That Develop in the Bone Marrow of Athymic Mice;Eleanor C. Tsark等;《The Journal of Immunology》;20010101;第166卷(第1期);第170-181页 *
Mechanisms of and perspectives on the mesenchymal stem cell in immunotherapy;ROBERT CHUNHUA ZHAO等;《Journal of Laboratory and Clinical Meddicine》;20040531;第143卷(第5期);第284-291页 *
Mesenchymal stem cells: A promising targeted-delivery vehicle in cancer gene therapy;Yu-Lan Hu等;《Journal of Controlled Release》;20101015;第147卷(第2期);第154-162页 *
Therapeutic potential of human mesenchymal stem cells producing IL-12 in a mouse xenograft model of renal cell carcinoma;Peng Gao 等，;《Cancer Letters》;20100428;第290卷(第2期);第157-158页"Abstract"、"Introduction"字段，第161页第3.6节 *
人白细胞介素12腺病毒载体构建及在人骨髓间充质干细胞中的表达;Chen Yuan-yuan等;《中国组织工程研究与临床康复》;20100604;第14卷(第23期);第4186-4190页 *

Also Published As

Publication number Publication date
US20170239297A1 (en) 2017-08-24
CA2956987C (en) 2023-03-21
IL250388B (en) 2021-02-28
EP3656387A3 (en) 2020-07-01
CN106659742A (zh) 2017-05-10
US20200268802A1 (en) 2020-08-27
EP3182984B1 (en) 2019-10-30
AU2015306231A1 (en) 2017-02-23
IL250388A0 (en) 2017-03-30
AU2015306231B2 (en) 2019-11-21
WO2016026854A2 (en) 2016-02-25
EP3656387A2 (en) 2020-05-27
US11464806B2 (en) 2022-10-11
JP2017525364A (ja) 2017-09-07
WO2016026854A3 (en) 2016-04-14
JP6712993B2 (ja) 2020-06-24
CA2956987A1 (en) 2016-02-25
EP3182984A2 (en) 2017-06-28

Similar Documents

Publication Publication Date Title
US11464806B2 (en) Genetically modified mesenchymal stem cells expressing an immune response-stimulating cytokine to attract and/or activate immune cells
US20230063829A1 (en) Mesenchymal stem cells to enhance anti-tumor activity of immunotherapy
JP2020011966A (ja) 増強された養子細胞療法
WO2016146819A1 (en) Hypoxia-induced expression of therapeutic proteins in mesenchymal stem cells
JP7820823B2 (ja) 骨髄性細胞およびミクログリアにおいて特異的に治療タンパク質を発現するウイルスベクター
CN101580817A (zh) 含有细胞因子诱导杀伤细胞的细胞群的制造方法
JP2022541293A (ja) がん細胞療法用のｐ２１発現単球
US10155024B2 (en) Composition for preventing or treating B-cell lymphoma comprising IL-21 expressing mesenchymal stem cells
CN116254230A (zh) 用于制备和扩增通用型人源化抗cd19 car-nk细胞的方法及其用途
HK1233546A1 (en) Genetically modified mesenchymal stem cells expressing an immune response-stimulating cytokine to attract and/or activate immune cells
HK1233546B (en) Genetically modified mesenchymal stem cells expressing an immune response-stimulating cytokine to attract and/or activate immune cells
WO2023276395A1 (ja) キメラサイトカイン受容体
CN119331907A (zh) Tcr-t细胞的制备方法及其产品
Vrohlings Unraveling the Mechanism of IL-12 Mediated Glioma Rejection
HK40001425B (en) Mesenchymal stem cells to enhance anti-tumor activity of immunotherapy
HK40001425A (en) Mesenchymal stem cells to enhance anti-tumor activity of immunotherapy

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant